Sixty patients with varicose veins, in the age range 25 to 52 years, entered the trial and were divided by random allocation into 2 equal groups. The first group received calcium dobesilate orally in dosage of 750 mg daily while the second remained untreated.
Out of 25 patients who completed the 3-month treatment course, clinical improvement occurred in 19 (76%). Mercury strain gauge plethysmography in those 19 patients showed a statistically significant mean fall in the venous distensibility index, in maximum venous outflow and in the capillary filtration coefficient after the course of calcium dobesilate. The mean erythrocyte sedimentation rate in the 25 patients fell from 40 mm in 1 hour (Westergren) before treatment to 10 mm at the end of the course. In 42% of the patients there was a fall in serum globulin concentration and correction of the albumin/globulin ratio and in 35% there was a slight fall in serum fibrinogen concentration. Possibly calcium dobesilate's known action in lowering blood viscosity contributes to its beneficial effect in varicose veins.
Get full access to this article
View all access options for this article.
References
1.
Altmann Canestri E., Leguizamon OG, Sanchez C., et al: Calcium dobesilate (Doxium) in the treatment of venous insufficiency. A pharmacological and clinical study. In: Proceedings of the Sixth World Congress of Phlebology, Buenos Aires , Argentina, 1977.
2.
Baricevic J. : Does calcium dobesilate (Doxium®) improve the microcirculation and the musculovenous pump in patients with varicose veins ? VASA9:240-245, 1980.
3.
Barnes RW, Collicott OE, Mozersky DJ, et al: Noninvasive quantitation of maximum venous outflow in acute thrombophlebitis. Surgery72:971-978, 1972.
4.
Barras JP, Graf C.: Hyperviscosity in diabetic retinopathy treated with Doxium® (calcium dobesilate) . VASA9:161-164, 1980.
5.
Berson I.: Un nouveau veinotrope de synthése en proctologie. Praxis61:52-54, 1972.
6.
Chant Adb, Jones HO, Weddell JM: Varicose veins: A comparison of surgery and injection/compression sclerotherapy . Lancet2:1188-1191, 1972 .
7.
Da Silva A., Widmer LK, Martin H., Mall T., Glaus L., Schneider M.: Varicose veins and chronic venous insufficiency. Prevalence and risk factors in 4376 subjects of the Basle Study II. VASA3:118-125, 1974.
8.
Eiriksson E. , Dann I.: Plethysmographic studies of venous distensibility in patients with varicose veins. Acta Chir Scand, Suppl398:19, 1968.
9.
Guberan E., Widmer LK, Glaus L., Muller R., Rougemont A., da Silva A., Gendre F.: Causative factors of varicose veins: Myths and facts. An epidemiological study of 610 women. VASA2:115-120, 1973.
10.
Hachen HJ, Lorenz P.: Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology33:480-488, 1982.
11.
Heidrich H. , Gerke E., Nekarda H.: Inhibition of platelet aggregation under calcium dobesilate. Arzneim-Forsch/Drug Res33(i), 4:580-582, 1983.
12.
Hudomel J., Nemeth B., Palfalvy M., Farkas A.: Effect of calcium dobesilate (Doxium®) on blood hyperviscosity in cases of diabetic retinopathy. Ophthalmic Res29:25-30, 1977.
13.
Kappert A.: Zur medikamentösen Beeinflussung gestörter Kapillarfunktionen. Z Ther12:71-89, 1974.
14.
Katz MA: Capillary filtration measurement by strain gauge. I. Analysis of methods. Am J Physiol232:H354-H360, 1977.
15.
Laszt L.: Zur Biochemie der Venenwand. In: J.R. Rüttner and H.J. Leu (eds.), Die Venenwand, 105-111, Huber, Bern, 1971.
16.
Niebes P., Berson I.: Determination of enzymes and degradation products of mucopolysaccharide metabolism in the serum of healthy and varicose subjects. Bibl Ana211:499-506, 1973.
17.
Pointel JP, Gin H., Drouin P., Vernhes G., Debry G.: Venous plethysmography: measuring techniques and normal values. Angiology32:145-154, 1981.
18.
Sévin R., Cuendet JF: Cinq années d'expérimentation avec le dobésilate de calcium dans le traitement des rétinopathies. Ophthalmologica, Basel170:232-238, 1975.
